The Filings Report

Krystal Biotech, Inc. Common Stock

KRYSNasdaqCIK 1711279Healthcare / Biotechnologyfiscal year ends December41 quarters since 2016

Revenue, Q3 FY2026
$127M
+30.2% on Q3 FY2025
Net income
$63M
−20.5% on Q3 FY2025
Free cash flow
$90M
+137.8% on Q3 FY2025
Diluted EPS
$2.05
−22.9% on Q3 FY2025
Revenue, TTM
$470M
trailing four quarters
Net margin, TTM
47.9%
net income $225M
Free cash flow, TTM
$310M
$324M less $14M capex
Cash and equivalents
$463M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+2.2%
30M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$8.9B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 2, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Krystal Biotech, Inc. Common Stock reported revenue of $127M, +30.2% on Q3 FY2025, and net income of $63M (−20.5%). Operating margin was 55.9%. Free cash flow, operating cash flow less capital expenditures, was $90M ($91M less $996K). Diluted earnings per share were $2.05.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

KRYS daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $298.31 · H $305.60 · L $297.52 · C $300.88 · +0.21% on the dayOver the range: +50.46%, Nov 7, 2025 to Nov 6, 2026
$181$234$288$341$394Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 2, 2026.

Revenue and net incomeRevenueNet income
−$50M$0$50M$100M$150MQ4'22, Revenue: $0Q4'22, Net income: −$32MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$45MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$33MQ2'23Q3'23, Revenue: $9MQ3'23, Net income: $81MQ3'23Q4'23, Revenue: $42MQ4'23, Net income: $9MQ4'23Q1'24, Revenue: $45MQ1'24, Net income: $932KQ1'24Q2'24, Revenue: $70MQ2'24, Net income: $16MQ2'24Q3'24, Revenue: $84MQ3'24, Net income: $27MQ3'24Q4'24, Revenue: $91MQ4'24, Net income: $45MQ4'24Q1'25, Revenue: $88MQ1'25, Net income: $36MQ1'25Q2'25, Revenue: $96MQ2'25, Net income: $38MQ2'25Q3'25, Revenue: $98MQ3'25, Net income: $79MQ3'25Q4'25, Revenue: $107MQ4'25, Net income: $51MQ4'25Q1'26, Revenue: $116MQ1'26, Net income: $56MQ1'26Q2'26, Revenue: $119MQ2'26, Net income: $55MQ2'26Q3'26, Revenue: $127MQ3'26, Net income: $63MQ3'26−$50M$0$50M$100M$150MQ4'22, Revenue: $0Q4'22, Net income: −$32MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$45MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$33MQ2'23Q3'23, Revenue: $9MQ3'23, Net income: $81MQ3'23Q4'23, Revenue: $42MQ4'23, Net income: $9MQ4'23Q1'24, Revenue: $45MQ1'24, Net income: $932KQ1'24Q2'24, Revenue: $70MQ2'24, Net income: $16MQ2'24Q3'24, Revenue: $84MQ3'24, Net income: $27MQ3'24Q4'24, Revenue: $91MQ4'24, Net income: $45MQ4'24Q1'25, Revenue: $88MQ1'25, Net income: $36MQ1'25Q2'25, Revenue: $96MQ2'25, Net income: $38MQ2'25Q3'25, Revenue: $98MQ3'25, Net income: $79MQ3'25Q4'25, Revenue: $107MQ4'25, Net income: $51MQ4'25Q1'26, Revenue: $116MQ1'26, Net income: $56MQ1'26Q2'26, Revenue: $119MQ2'26, Net income: $55MQ2'26Q3'26, Revenue: $127MQ3'26, Net income: $63MQ3'26−$50M$0$50M$100M$150MQ4'22, Revenue: $0Q4'22, Net income: −$32MQ1'23, Revenue: $0Q1'23, Net income: −$45MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$33MQ3'23, Revenue: $9MQ3'23, Net income: $81MQ3'23Q4'23, Revenue: $42MQ4'23, Net income: $9MQ1'24, Revenue: $45MQ1'24, Net income: $932KQ1'24Q2'24, Revenue: $70MQ2'24, Net income: $16MQ3'24, Revenue: $84MQ3'24, Net income: $27MQ3'24Q4'24, Revenue: $91MQ4'24, Net income: $45MQ1'25, Revenue: $88MQ1'25, Net income: $36MQ1'25Q2'25, Revenue: $96MQ2'25, Net income: $38MQ3'25, Revenue: $98MQ3'25, Net income: $79MQ3'25Q4'25, Revenue: $107MQ4'25, Net income: $51MQ1'26, Revenue: $116MQ1'26, Net income: $56MQ1'26Q2'26, Revenue: $119MQ2'26, Net income: $55MQ3'26, Revenue: $127MQ3'26, Net income: $63MQ3'26

Net income losses drawn in red.

Free cash flow
−$50M$0$50M$100MQ4'22, Free cash flow: −$28MQ4'22Q1'23, Free cash flow: −$32MQ1'23Q2'23, Free cash flow: −$37MQ2'23Q3'23, Free cash flow: −$23MQ3'23Q4'23, Free cash flow: −$9MQ4'23Q1'24, Free cash flow: $15MQ1'24Q2'24, Free cash flow: −$5MQ2'24Q3'24, Free cash flow: $58MQ3'24Q4'24, Free cash flow: $52MQ4'24Q1'25, Free cash flow: $25MQ1'25Q2'25, Free cash flow: $51MQ2'25Q3'25, Free cash flow: $38MQ3'25Q4'25, Free cash flow: $75MQ4'25Q1'26, Free cash flow: $73MQ1'26Q2'26, Free cash flow: $71MQ2'26Q3'26, Free cash flow: $90MQ3'26−$50M$0$50M$100MQ4'22, Free cash flow: −$28MQ4'22Q1'23, Free cash flow: −$32MQ1'23Q2'23, Free cash flow: −$37MQ2'23Q3'23, Free cash flow: −$23MQ3'23Q4'23, Free cash flow: −$9MQ4'23Q1'24, Free cash flow: $15MQ1'24Q2'24, Free cash flow: −$5MQ2'24Q3'24, Free cash flow: $58MQ3'24Q4'24, Free cash flow: $52MQ4'24Q1'25, Free cash flow: $25MQ1'25Q2'25, Free cash flow: $51MQ2'25Q3'25, Free cash flow: $38MQ3'25Q4'25, Free cash flow: $75MQ4'25Q1'26, Free cash flow: $73MQ1'26Q2'26, Free cash flow: $71MQ2'26Q3'26, Free cash flow: $90MQ3'26−$50M$0$50M$100MQ4'22, Free cash flow: −$28MQ1'23, Free cash flow: −$32MQ1'23Q2'23, Free cash flow: −$37MQ3'23, Free cash flow: −$23MQ3'23Q4'23, Free cash flow: −$9MQ1'24, Free cash flow: $15MQ1'24Q2'24, Free cash flow: −$5MQ3'24, Free cash flow: $58MQ3'24Q4'24, Free cash flow: $52MQ1'25, Free cash flow: $25MQ1'25Q2'25, Free cash flow: $51MQ3'25, Free cash flow: $38MQ3'25Q4'25, Free cash flow: $75MQ1'26, Free cash flow: $73MQ1'26Q2'26, Free cash flow: $71MQ3'26, Free cash flow: $90MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600MQ4'22, Cash and equivalents: $162MQ4'22Q1'23, Cash and equivalents: $141MQ1'23Q2'23, Cash and equivalents: $276MQ2'23Q3'23, Cash and equivalents: $373MQ3'23Q4'23, Cash and equivalents: $358MQ4'23Q1'24, Cash and equivalents: $359MQ1'24Q2'24, Cash and equivalents: $346MQ2'24Q3'24, Cash and equivalents: $374MQ3'24Q4'24, Cash and equivalents: $345MQ4'24Q1'25, Cash and equivalents: $309MQ1'25Q2'25, Cash and equivalents: $354MQ2'25Q3'25, Cash and equivalents: $393MQ3'25Q4'25, Cash and equivalents: $496MQ4'25Q1'26, Cash and equivalents: $501MQ1'26Q2'26, Cash and equivalents: $428MQ2'26Q3'26, Cash and equivalents: $463MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $162MQ4'22Q1'23, Cash and equivalents: $141MQ1'23Q2'23, Cash and equivalents: $276MQ2'23Q3'23, Cash and equivalents: $373MQ3'23Q4'23, Cash and equivalents: $358MQ4'23Q1'24, Cash and equivalents: $359MQ1'24Q2'24, Cash and equivalents: $346MQ2'24Q3'24, Cash and equivalents: $374MQ3'24Q4'24, Cash and equivalents: $345MQ4'24Q1'25, Cash and equivalents: $309MQ1'25Q2'25, Cash and equivalents: $354MQ2'25Q3'25, Cash and equivalents: $393MQ3'25Q4'25, Cash and equivalents: $496MQ4'25Q1'26, Cash and equivalents: $501MQ1'26Q2'26, Cash and equivalents: $428MQ2'26Q3'26, Cash and equivalents: $463MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $162MQ1'23, Cash and equivalents: $141MQ1'23Q2'23, Cash and equivalents: $276MQ3'23, Cash and equivalents: $373MQ3'23Q4'23, Cash and equivalents: $358MQ1'24, Cash and equivalents: $359MQ1'24Q2'24, Cash and equivalents: $346MQ3'24, Cash and equivalents: $374MQ3'24Q4'24, Cash and equivalents: $345MQ1'25, Cash and equivalents: $309MQ1'25Q2'25, Cash and equivalents: $354MQ3'25, Cash and equivalents: $393MQ3'25Q4'25, Cash and equivalents: $496MQ1'26, Cash and equivalents: $501MQ1'26Q2'26, Cash and equivalents: $428MQ3'26, Cash and equivalents: $463MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Krystal Biotech, Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue12711911610798968891+30.2%
Cost of revenue—————————
Gross profit—————————
Research and development1515151515141414+2.1%
Selling, general and administrative3440414138353331−10.2%
Operating income7158544441393641+72.0%
Other income (expense)—————————
Pretax income8066615148474449+67.1%
Income tax171160(31)883+154.4%
Net income6355565179383645−20.5%
Diluted EPS ($)2.051.791.83—2.661.291.20—−22.9%
Diluted shares (millions)313131—303030——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Krystal Biotech, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents463428501496393354309345+17.9%
Short-term investments449418322331338328308253+32.7%
Total current assets1,1221,0601,0201,025926841767742+21.2%
Total assets1,5861,5011,3971,3341,2401,1381,0741,056+27.9%
Total current liabilities142127108103918779102+55.7%
Long-term debt—————————
Total liabilities1501421201141029890109+47.2%
Stockholders’ equity1,4361,3591,2771,2201,1381,041985946+26.2%
Shares outstanding (millions)3030292929292929—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Krystal Biotech, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow9175807840533153+130.1%
Capital expenditures14722261−41.5%
Free cash flow (CFO − capex)9071737538512552+137.8%
Depreciation and amortization—————————
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 17, 2026.

Income statement

Krystal Biotech, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 10, 2020FY2018ended Dec 31, 2018filed May 7, 2019FY2017ended Dec 31, 2017filed Mar 12, 2018FY2016ended Dec 31, 2016filed Nov 13, 2017
Revenue3892915100—————
Cost of revenue——————————
Gross profit——————————
Research and development58544642281816831
Selling, general and administrative147114987840156420
Operating income16166(110)(145)(68)(33)(22)(12)(5)(1)
Other income (expense)————————(3)0
Pretax income1899513(140)(70)—————
Income tax(15)62000000—
Net income2058911(140)(70)(32)(19)(11)(8)(1)
Diluted EPS ($)6.843.000.39(5.49)(3.13)(1.71)————
Diluted shares (millions)303028252219————

Balance sheet

Krystal Biotech, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 10, 2020FY2018ended Dec 31, 2018filed May 7, 2019FY2017ended Dec 31, 2017filed Mar 12, 2018FY2016ended Dec 31, 2016filed Nov 13, 2017
Cash and equivalents496345358162341268188104502
Short-term investments33125317421797368——
Total current assets1,025742588384442275196113502
Total assets1,3341,056818558626311209116502
Total current liabilities103102332926153310
Long-term debt——————————
Total liabilities114109403633196312
Stockholders’ equity1,220946779522594292203113490
Shares outstanding (millions)292928262522171410—

Cash flow statement

Krystal Biotech, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 10, 2020FY2018ended Dec 31, 2018filed May 7, 2019FY2017ended Dec 31, 2017filed Mar 12, 2018FY2016ended Dec 31, 2016filed Nov 13, 2017
Operating cash flow201123(89)(101)(48)(26)(19)(9)——
Capital expenditures124125368156200
Free cash flow (CFO − capex)189119(101)(154)(116)(41)(25)(12)——
Depreciation and amortization———4321———
Share repurchases——————————
Dividends paid——————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$26M
34 sales by 3 insiders; officers and directors $26M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$105M
142 sales by 6 insiders; officers and directors $105M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-1520$354.54$184K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-12,006$355.57$713K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-13,267$356.37$1M1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-13,962$357.57$1M1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-13,180$358.42$1M1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-13,392$359.39$1M1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-12,320$360.47$836K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-11,242$361.61$449K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-11,992$362.65$722K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-1565$363.34$205K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-11,329$364.48$484K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-1826$365.41$302K1MSep 4, 2026
Sep 4, 2026Krishnan SumaPresident, R&D, Director, 10% owneropen-market sale10b5-1399$366.56$146K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-1520$354.54$184K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-12,029$355.57$721K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-13,297$356.37$1M1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-13,981$357.57$1M1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-13,143$358.42$1M1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-13,357$359.39$1M1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-12,266$360.46$817K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-11,214$361.61$439K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-12,010$362.65$729K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-1573$363.34$208K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-11,358$364.48$495K1MSep 4, 2026
Sep 4, 2026Krishnan Krish SPresident and CEO, Director, 10% owneropen-market sale10b5-1847$365.42$310K1MSep 4, 2026

Full insider history for Krystal Biotech, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Krystal Biotech, Inc., CIK 1711279 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2017
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/KRYS.json